The record
Written from the 1 report below. Nothing here is unsourced.
- The Ministry of Health and Family Welfare approved the Biovigilance Programme of India to track side effects related to organ and tissue transplant products.
- The Indian Pharmacopoeia Commission will oversee the initiative, which will also integrate reporting mechanisms into primary health centres.
- Plans include leveraging mobile applications and QR codes to improve patient reporting of adverse reactions.
- This effort expands India's existing safety-monitoring infrastructure for drugs and medical devices.
What to watch next
- Expansion of pharmacovigilance systems to primary health centres
- Implementation of AI-based approaches for drug safety monitoring
- Reduction of animal experimentation in monograph development
Who said what3
Only words found exactly in the article are shown, attributed and linked to the line they came from.
V Kalaiselvan
IPC Secretary-cum-Scientific Director
3 quotes · 1 outlet
“The necessary tools are available for them like digital tools, mobile app, QR code, all will be available to the primary health centre to report adverse events”
In the article
…Connecting with PHCs Kalaiselvan said the commission was working with its regional monitoring centres to connect with communities and primary health centres and enable them to participate in pharmacovigilance. “ The necessary tools are available for them like digital tools, mobile app, QR code, all will be available to the primary health centre to report adverse events ,” he said. The planned expansion will build on IPC’s existing digital reporting mechanisms, including its Adverse Drug Monitoring System (ADRMS), mobile-based reporting and QR-code facilities. The ADRMS is an online…
“We are not only focusing on the safety of medicines, we are also focusing on medical devices, blood and blood products and many more products”
In the article
…awareness about adverse events related to medical products. The commission is also broadening its safety-monitoring work beyond medicines to medical devices, blood and blood products and other medical products. “ We are not only focusing on the safety of medicines, we are also focusing on medical devices, blood and blood products and many more products ,” Kalaiselvan said. Animal Experimentation Alongside safety monitoring, IPC is working to reduce the environmental and ethical burden associated with developing pharmacopoeial standards. Kalaiselvan said the commission…
Coverage1
All filed from India
Named India · Anupriya Patel · Indian Pharmacopoeia Commission · Ministry of Health and Family Welfare · V Kalaiselvan
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.